Literature DB >> 26366808

The etiology and therapy of primary spontaneous pneumothoraces.

Hsao-Hsun Hsu1, Jin-Shing Chen1,2.   

Abstract

Primary spontaneous pneumothorax (PSP) remains a significant health problem in young adults. Subpleural blebs and bullae in the lung apices are likely to play important roles in pathogenesis. The optimal management of PSP has been a matter of debate and depends on the size of the pneumothorax, the symptoms and the time of occurrence. Observation or simple aspiration is used in the first episode, while surgery is recommended for recurrent or complicated pneumothorax. Recent advances in thoracoscopic surgery have provided a less invasive alternative in the surgical treatment of PSP, but there are concerns about higher recurrence rates than that following open thoracotomy. Studies have shown that the judicious use of chemical pleurodesis may decrease the rate of recurrence in surgical and nonsurgical patients. In this article, the etiology and pathophysiology of PSP are reviewed. The indications, safety and effects of currently available treatment modalities are also summarized.

Entities:  

Keywords:  aspiration; etiology; pleurodesis; pneumothorax; thoracoscopy; treatment

Mesh:

Year:  2015        PMID: 26366808     DOI: 10.1586/17476348.2015.1083427

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  2 in total

1.  Primary and Secondary Spontaneous Pneumothorax: Prevalence, Clinical Features, and In-Hospital Mortality.

Authors:  Takuya Onuki; Sho Ueda; Masatoshi Yamaoka; Yoshiaki Sekiya; Hitoshi Yamada; Naoki Kawakami; Yuichi Araki; Yoko Wakai; Kazuhito Saito; Masaharu Inagaki; Naoki Matsumiya
Journal:  Can Respir J       Date:  2017-03-13       Impact factor: 2.409

2.  Next-day discharge following small uniportal thoracoscopic bullectomy assisted with an anchoring suture.

Authors:  Chu Zhang; Miao Zhang; Haiyong Wang; Zhifeng Ma; Yuanlin Wu; Linhai Fu; Ting Zhu; Guangmao Yu
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.